PARP Inhibitors in Prostate Cancer

Oliver Sartor, MD, describes the different tests routinely ordered for metastatic prostate cancer.

An expert oncologist discusses the biomarker testing targets in metastatic prostate cancer.

Dr. Oliver Sartor illustrates the systemic treatment options for metastatic castration-resistant prostate cancer and what to consider when choosing therapies.

A key opinion leader explains the role of PARP inhibitors in metastatic prostate cancer and reviews clinical trial data.

Oliver Sartor, MD, discusses the use of rucaparib in treating metastatic prostate cancer.

A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.

Alicia Morgans, MD, MPH, explains the different testing that should be done when being diagnosed with metastatic prostate cancer.

Dr Morgans discusses biomarker testing protocols and signs to look for during testing.

An expert considers the role of BRCA1/2 mutations in metastatic prostate cancer.

Dr Morgans examines systemic treatment options for patients with metastatic castration-resistant prostate cancer.

Alicia Morgans, MD, MPH, discusses how to select the best treatment for patients with metastatic prostate cancer and the importance of monitoring them while on therapy.

An expert explains PARP inhibitor use in the metastatic prostate cancer treatment landscape and typical adverse events seen during therapies.

Alicia Morgans, MD, MPH, mentions other factors clinicians need to consider before adding PARP inhibitors to metastatic prostate cancer therapy.

Dr Morgans discusses how patient access impacts treating metastatic prostate cancer.

An expert examines sequencing strategies for the treatment of metastatic prostate cancer.

Alicia Morgans, MD, MPH, lists several advances being made while treating metastatic prostate cancer and offers advice to clinicians who don’t see patients with the disease very often.

A. Oliver Sartor, MD, discussen treatment options for PARP inhibitor use in patients with prostate cancer.

Alicia Morgans, MD, discusses genomic testing and use of PARP inhibitors for metastatic castration-resistant prostate cancer.